Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Santini Daniele, Barni Sandro, Intagliata Salvatore, Falcone Alfredo, Ferraù Francesco, Galetta Domenico, Moscetti Luca, La Verde Nicla, Ibrahim Toni, Petrelli Fausto, Vasile Enrico, Ginocchi Laura, Ottaviani Davide, Longo Flavia, Ortega Cinzia, Russo Antonio, Badalamenti Giuseppe, Collovà Elena, Lanzetta Gaetano, Mansueto GiovanniAdamo Vincenzo, De Marinis Filippo, Satolli Maria Antonietta, Cantile Flavia, Mancuso Andrea, Francesca Maria Tanca, Addeo Raffaele, Russano Marco, M. Sterpi, Pantano Francesco, Vincenzi Bruno, Tonini Giuseppe

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.

Original languageEnglish
Article number18670
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Dec 22 2015

Fingerprint

Bone Neoplasms
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Bone and Bones
Survival
Clinical Pathology
Histology
Radiotherapy

ASJC Scopus subject areas

  • General

Cite this

Daniele, S., Sandro, B., Salvatore, I., Alfredo, F., Francesco, F., Domenico, G., ... Giuseppe, T. (2015). Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Scientific Reports, 5, [18670]. https://doi.org/10.1038/srep18670

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. / Daniele, Santini; Sandro, Barni; Salvatore, Intagliata; Alfredo, Falcone; Francesco, Ferraù; Domenico, Galetta; Luca, Moscetti; Nicla, La Verde; Toni, Ibrahim; Fausto, Petrelli; Enrico, Vasile; Laura, Ginocchi; Davide, Ottaviani; Flavia, Longo; Cinzia, Ortega; Antonio, Russo; Giuseppe, Badalamenti; Elena, Collovà; Gaetano, Lanzetta; Giovanni, Mansueto; Vincenzo, Adamo; Filippo, De Marinis; Antonietta, Satolli Maria; Flavia, Cantile; Andrea, Mancuso; Tanca, Francesca Maria; Raffaele, Addeo; Marco, Russano; Sterpi, M.; Francesco, Pantano; Bruno, Vincenzi; Giuseppe, Tonini.

In: Scientific Reports, Vol. 5, 18670, 22.12.2015.

Research output: Contribution to journalArticle

Daniele, S, Sandro, B, Salvatore, I, Alfredo, F, Francesco, F, Domenico, G, Luca, M, Nicla, LV, Toni, I, Fausto, P, Enrico, V, Laura, G, Davide, O, Flavia, L, Cinzia, O, Antonio, R, Giuseppe, B, Elena, C, Gaetano, L, Giovanni, M, Vincenzo, A, Filippo, DM, Antonietta, SM, Flavia, C, Andrea, M, Tanca, FM, Raffaele, A, Marco, R, Sterpi, M, Francesco, P, Bruno, V & Giuseppe, T 2015, 'Natural History of Non-Small-Cell Lung Cancer with Bone Metastases', Scientific Reports, vol. 5, 18670. https://doi.org/10.1038/srep18670
Daniele S, Sandro B, Salvatore I, Alfredo F, Francesco F, Domenico G et al. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Scientific Reports. 2015 Dec 22;5. 18670. https://doi.org/10.1038/srep18670
Daniele, Santini ; Sandro, Barni ; Salvatore, Intagliata ; Alfredo, Falcone ; Francesco, Ferraù ; Domenico, Galetta ; Luca, Moscetti ; Nicla, La Verde ; Toni, Ibrahim ; Fausto, Petrelli ; Enrico, Vasile ; Laura, Ginocchi ; Davide, Ottaviani ; Flavia, Longo ; Cinzia, Ortega ; Antonio, Russo ; Giuseppe, Badalamenti ; Elena, Collovà ; Gaetano, Lanzetta ; Giovanni, Mansueto ; Vincenzo, Adamo ; Filippo, De Marinis ; Antonietta, Satolli Maria ; Flavia, Cantile ; Andrea, Mancuso ; Tanca, Francesca Maria ; Raffaele, Addeo ; Marco, Russano ; Sterpi, M. ; Francesco, Pantano ; Bruno, Vincenzi ; Giuseppe, Tonini. / Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. In: Scientific Reports. 2015 ; Vol. 5.
@article{ea55e11e2a04448e92d0491ef6a1099a,
title = "Natural History of Non-Small-Cell Lung Cancer with Bone Metastases",
abstract = "We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5{\%} of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6{\%} of patients. Skeletal-related events were experienced by 57.7{\%} of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.",
author = "Santini Daniele and Barni Sandro and Intagliata Salvatore and Falcone Alfredo and Ferra{\`u} Francesco and Galetta Domenico and Moscetti Luca and Nicla, {La Verde} and Ibrahim Toni and Petrelli Fausto and Vasile Enrico and Ginocchi Laura and Ottaviani Davide and Longo Flavia and Ortega Cinzia and Russo Antonio and Badalamenti Giuseppe and Collov{\`a} Elena and Lanzetta Gaetano and Mansueto Giovanni and Adamo Vincenzo and Filippo, {De Marinis} and Antonietta, {Satolli Maria} and Cantile Flavia and Mancuso Andrea and Tanca, {Francesca Maria} and Addeo Raffaele and Russano Marco and M. Sterpi and Pantano Francesco and Vincenzi Bruno and Tonini Giuseppe",
year = "2015",
month = "12",
day = "22",
doi = "10.1038/srep18670",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

AU - Daniele, Santini

AU - Sandro, Barni

AU - Salvatore, Intagliata

AU - Alfredo, Falcone

AU - Francesco, Ferraù

AU - Domenico, Galetta

AU - Luca, Moscetti

AU - Nicla, La Verde

AU - Toni, Ibrahim

AU - Fausto, Petrelli

AU - Enrico, Vasile

AU - Laura, Ginocchi

AU - Davide, Ottaviani

AU - Flavia, Longo

AU - Cinzia, Ortega

AU - Antonio, Russo

AU - Giuseppe, Badalamenti

AU - Elena, Collovà

AU - Gaetano, Lanzetta

AU - Giovanni, Mansueto

AU - Vincenzo, Adamo

AU - Filippo, De Marinis

AU - Antonietta, Satolli Maria

AU - Flavia, Cantile

AU - Andrea, Mancuso

AU - Tanca, Francesca Maria

AU - Raffaele, Addeo

AU - Marco, Russano

AU - Sterpi, M.

AU - Francesco, Pantano

AU - Bruno, Vincenzi

AU - Giuseppe, Tonini

PY - 2015/12/22

Y1 - 2015/12/22

N2 - We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.

AB - We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.

UR - http://www.scopus.com/inward/record.url?scp=84951835988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951835988&partnerID=8YFLogxK

U2 - 10.1038/srep18670

DO - 10.1038/srep18670

M3 - Article

AN - SCOPUS:84951835988

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 18670

ER -